Amgen Inc. (AMGN) earnings on November 3, 2026
Prior outlook: Optimistic Outcome: Accurate
AMGN rose after earnings, as analysts raised their expected prices for the stock.
AMGN price around the earnings
478.48
Change: +3.7%
2026-11-04, 21:00 UTC
- Price: green if it ends above the starting price; red if it ends below
- Start of the measured window
- End of the measured window
- Market open
- No trading (market closed)
- Starting price
Prior thesis
Prior outlook: Optimistic Outcome: Accurate
- Thesis published
- Results released
Optimistic scenario
The setup points optimistic: AMGN has strong recent trend strength and has beaten earnings expectations in recent quarters. Analysts are more cautious, but the price structure carries more weight in this view.
Context analyzed before publication
- Summary
- Optimistic scenario
- Playbook
- AMGN has outperformed the Nasdaq-100 ETF over 30 days and sits near its 52-week high, while analysts' targets remain below the current price.
- Trend
- Optimistic outlook persists despite score fluctuations
Analysts
Drivers
-
Analysts
Negative
Most analysts rate AMGN Hold across 29 opinions, with a slightly negative tilt, while the scenario points optimistic despite a stated $397 target.
Evidence
- Analyst consensus
- Hold
- Consensus average (1-5)
- 2.65
- Analysts covering the stock
- 29
- Average price target
- 397.32
- Lowest price target
- 225
- Highest price target
- 500
- Upside to price target
- -13.8%
- Quarterly earnings growth
- 65.9%
- Revenue growth
- 9.5%
- Forward EPS
- 24.5
- Trailing EPS
- 16.1
- Analyst moves in the last 60 days
- 10
- Strong buy: 4
- Buy: 8
- Hold: 17
- Sell: 3
- Strong sell: 2
- Strong buy
- 4
- Buy
- 8
- Hold
- 17
- Sell
- 3
- Strong sell
- 2
- October 23, 2026 · Oppenheimer: Maintains rating (Outperform → Outperform)
- October 21, 2026 · Barclays: Maintains rating (Equal-Weight → Equal-Weight)
- October 13, 2026 · Guggenheim: Maintains rating (Neutral → Neutral)
- October 12, 2026 · BMO Capital: Maintains rating (Market Perform → Market Perform)
- October 12, 2026 · Wells Fargo: Maintains rating (Equal-Weight → Equal-Weight)
- October 9, 2026 · UBS: Maintains rating (Buy → Buy)
- October 8, 2026 · RBC Capital: Maintains rating (Outperform → Outperform)
- October 8, 2026 · Cantor Fitzgerald: Maintains rating (Neutral → Neutral)
- October 7, 2026 · Truist Securities: Maintains rating (Hold → Hold)
- October 7, 2026 · Morgan Stanley: Maintains rating (Equal-Weight → Equal-Weight)
News and sentiment
Drivers
-
News & sentiment
Neutral
The headlines focus on broad market themes rather than AMGN specifically, and optimistic social-media discussion has limited supporting evidence.
Evidence
Sentiment
- Sentiment
- Constructive
- Mention volume
- High
- Normalized volume
- 99%
- Messages
- 30
News
Sources (6)
- Amgen Continues Phase III Clinical Trial for Pegloticase in Uncontrolled Gout (opens in a new tab) — fiscal.ai
- FDA Reviews Amgen's Video for VECTIBIX Injection (opens in a new tab) — fiscal.ai
- Amgen Announces Webcast for 2026 Third Quarter Financial Results (opens in a new tab) — fiscal.ai
- Regeneron and Amgen Narrow Scope of Eylea Biosimilar Lawsuit (opens in a new tab) — fiscal.ai
- Amgen Declares Fourth Quarter 2026 Dividend (opens in a new tab) — fiscal.ai
- Amgen Announces Upcoming Data Presentations for ACR Convergence 2026 (opens in a new tab) — fiscal.ai
Technicals
Drivers
-
Technical
Positive
Over the past 30 days, AMGN gained 15.47% while the Nasdaq-100 ETF fell 9.11%, showing stronger performance by 24.58 percentage points.
Evidence
- Price when the context was analyzed
- 465.45
- Average true range (ATR)
- 2.4%
- Distance to 52-week high
- -1.1%
- 14-day change (14d)
- +9.5%
- 30-day change (31d)
- +15.5%
- 30-day relative strength
- +24.6%
- QQQ change (31d)
- -9.1%
- Nearest support
- 465.25
- Distance to nearest support
- 0%
- Nearest resistance
- 468.08
- Distance to nearest resistance
- 0.6%
- Volume accumulation ratio (14d / 46d)
- 0.96
- Minor: 465.25 (0% away, 0.02 ATR, 4 touches)
- Mid: 460.92 (1% away, 0.4 ATR, 6 touches)
- Minor: 457.4 (1.7% away, 0.72 ATR, 2 touches)
- Mid: 468.08 (0.6% away, 0.24 ATR, 9 touches)
- Minor: 472.99 (1.6% away, 0.67 ATR, 3 touches)
Trends
Drivers
-
Macro & trends
Positive
A 15.47% gain over 30 days places AMGN near its 52-week high and shows clear trend strength.
Evidence
- Average earnings surprise
- +11.1%
- August 4, 2026: actual EPS 6.29 vs estimate 5.62 (surprise +12.0%)
- April 30, 2026: actual EPS 5.15 vs estimate 4.77 (surprise +8.0%)
- February 3, 2026: actual EPS 5.29 vs estimate 4.73 (surprise +11.9%)
- November 4, 2025: actual EPS 5.64 vs estimate 5.01 (surprise +12.5%)
Expected move
Drivers
-
Past earnings
Positive
The last four reported earnings-per-share results exceeded analyst estimates by 8.0% to 12.5%, though market reactions after results have been mixed.
- Implied move
- +3.1%
- Source
- Options chain
Reactions over its last 21 earnings
- Median move
- 4.7%
- 75th percentile move
- 6.4%
- 90th percentile move
- 7.9%
- Up / down moves
- 10 / 11
- Average up move
- +5.6%
- Average down move
- -3.5%
Monitoring and close
What Amgen Inc. reported
- Status
- Finished
| Actual EPS | 6.45 |
|---|---|
| EPS estimate | 5.79 |
| EPS surprise | +11.4% |
| Revenue | $10,365 million |
| Revenue estimate | $10,071 million |
| Revenue surprise | +2.9% |
Amgen beat Q3 estimates and raised 2026 guidance, with shares up 5.91%. Adjusted EPS reached $6.45 versus $5.76 expected, while revenue was $10.40 billion.
Sources (39)
- JP Morgan Maintains Neutral on Amgen, Raises Price Target to $425 (opens in a new tab) — Benzinga
- TD Cowen Maintains Buy on Amgen, Raises Price Target to $531 (opens in a new tab) — Benzinga
- Amgen earnings analysis: questions answered and next catalysts (opens in a new tab) — Yahoo
- Goldman Sachs Maintains Buy on Amgen, Raises Price Target to $536 (opens in a new tab) — Benzinga
- Amgen Analyst Likes Diversified Business, Remains Patient Until MariTide Obesity Data (opens in a new tab) — Benzinga
- Morgan Stanley Maintains Equal-Weight on Amgen, Raises Price Target to $410 (opens in a new tab) — Benzinga
- Amgen Stocks Rise 5.91% as Higher Guidance Narrows the Remaining Earnings Test (opens in a new tab) — Yahoo
- RBC Capital Maintains Outperform on Amgen, Raises Price Target to $470 (opens in a new tab) — Benzinga
- Truist Securities Maintains Hold on Amgen, Raises Price Target to $398 (opens in a new tab) — Benzinga
- Wells Fargo Maintains Equal-Weight on Amgen, Raises Price Target to $460 (opens in a new tab) — Benzinga
- Amgen (AMGN) Q3 2026 Earnings Call Transcript (opens in a new tab) — Yahoo
- $1000 Invested In Amgen 15 Years Ago Would Be Worth This Much Today (opens in a new tab) — Benzinga
- AMGN Q3 Earnings Call Highlights Pipeline and Raised Outlook (opens in a new tab) — Yahoo
- Stock Market Today: Dow Jones, S&P 500, Nasdaq 100 Futures Rise as Democrats Take Control of Congress—AMD, AMGN, NVO in Focus (UPDATED) (opens in a new tab) — Benzinga
- Analysts Adjust Price Targets for Amgen Following Q3 Results (opens in a new tab) — fiscal.ai
- AMGN Stock Down Despite Q3 Earnings & Sales Beat, Raised Guidance (opens in a new tab) — Yahoo
- How Investors May Respond To Amgen (AMGN) Earnings Beat (opens in a new tab) — Yahoo
- Cantor Fitzgerald Maintains Neutral on Amgen, Raises Price Target to $465 (opens in a new tab) — Benzinga
- Amgen Announces Positive Phase 3 Clinical Results and FDA Labeling Update (opens in a new tab) — fiscal.ai
- Stock Market Today: Dow Jones, S&P 500 Futures Rise as Democrats Take Control of Congress—AMD, AMGN, NVO in Focus (opens in a new tab) — Benzinga
- Amgen Inc (AMGN) (Q3 2026) Earnings Call Highlights: Revenue Up 8% to $10. ... (opens in a new tab) — Yahoo
- What Amgen (AMGN) Said on Its Q3 Earnings Call (opens in a new tab) — Yahoo
- Amgen (NASDAQ:AMGN) Q3 2026: EPS Beat, Revenue In Line as Shares Dip After-Hours (opens in a new tab) — ChartMill
- Amgen Inc. (AMGN) Q3 2026 Earnings Call Transcript (opens in a new tab) — SeekingAlpha
- Amgen Q3 2026 Earnings Call Transcript (opens in a new tab) — Benzinga
- Amgen (AMGN) Reports Q3 Earnings: What Key Metrics Have to Say (opens in a new tab) — Yahoo
- Amgen (NASDAQ:AMGN) exceeds Q3 2026 expectations, full-year outlook slightly exceeds expectations (opens in a new tab) — Yahoo
- Stock Market Election Night Live Coverage: Dow Futures, AI Stocks, Elon Musk In Focus; AMD, Arista, Amgen, Astera Move On Earnings (opens in a new tab) — Yahoo
- Amgen beats estimates but shares dip on biosimilar concerns (opens in a new tab) — Yahoo
- Amgen Raises Full-Year Outlook Following Strong Third-Quarter Results (opens in a new tab) — fiscal.ai
- Amgen, Up 41% This Year, Is Broadly Outperforming Its Peers. Here's What Its Earnings Say. (opens in a new tab) — Yahoo
- Amgen (AMGN) Tops Q3 Earnings and Revenue Estimates (opens in a new tab) — Yahoo
- Amgen: Q3 Earnings Snapshot (opens in a new tab) — Yahoo
- Amgen Raises FY2026 Adj EPS Guidance from $22.30-$23.50 to $22.90-$23.70 vs $23.02 Est; Raises FY2026 Sales Guidance from $38.200B-$39.400B to $38.900B-$39.700B vs $38.936B Est (opens in a new tab) — Benzinga
- Amgen Raises FY2026 GAAP EPS Guidance from $15.80-$17.08 to $18.34-$19.28 vs $15.90 Est (opens in a new tab) — Benzinga
- Amgen reported adjusted earnings of $6.45 per share, above the $5.79 estimate, and sales of $10.365 billion, above the $10.071 billion estimate. — Benzinga
- Amgen Q3 Adj. EPS $6.45 Beats $5.79 Estimate, Sales $10.365B Beat $10.071B Estimate (opens in a new tab) — Benzinga
- AMGEN REPORTS THIRD QUARTER 2026 FINANCIAL RESULTS (opens in a new tab) — Yahoo
- Amgen Inc. 2026 Q3 - Results - Earnings Call Presentation (opens in a new tab) — SeekingAlpha
Pre-market second reading after the results
- Verdict
- Beat expectations
Heading into the open, Results beat expectations on both earnings and revenue and the price is indicating +5.6% pre-market, a move in line with the stock's usual reaction (about 5%). The figures confirm the optimistic scenario. Across our market history, in the 1,193 similar cases the close held that direction 84% of the time.
How the stock reacted
- Outcome
- Accurate
- Consolidated
- +3.7%
- Max favorable move (MFE)
- 7.2%
- Max adverse move (MAE)
- 2.9%